COMPANY

Eclipse Regenesis, Inc.

Also known as Eclipse Regenesis · 2 sources

Location: Mountain View, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $861K (SBIR Phase II 5R44DK127658-05, continuation, notice Aug 21, 2026). NIH RePORTER 5R44DK127658-05 (Aug 21, 2026)
Evidence (1 event)
- Aug 21, 2026 · NIH RePORTER 5R44DK127658-05
  Organization: ECLIPSE ENTEROGENESIS, INC.; City/State: MENLO PARK, CA; Project number: 5R44DK127658-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 860948; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Outcomes study for the XL1 distraction enterogenesis device to improve nutrient absorption in short bowel syndrome patients; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Aug 21, 2026 Grant Government grant — SBIR: $860,948 (annual award, as published), announced Aug 21, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Sep 11, 2025 Grant Government grant — SBIR: $856,731 (annual award, as published), announced Sep 11, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗

Last 2 years.

Aug 21, 2026 Government grant — SBIR: $860,948 (annual award, as published), announced Aug 21, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Sep 11, 2025 Government grant — SBIR: $856,731 (annual award, as published), announced Sep 11, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗